Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies—the role of HAS2, SHB and HBEGF

Fig. 4

Confirmation of trastuzumab candidate biomarkers BMF, HAS2, and SHB. MKN1 a cells were treated with EGF, EGF plus cetuximab (EGF + Cet), cetuximab (Cet), trastuzumab (Tra), afatinib (Afa) or trastuzumab plus afatinib (Tra + Afa). NCI-N87 b, c, d were treated with trastuzumab (Tra), afatinib (Afa) or trastuzumab plus afatinib (Tra + Afa). The selected treatment times were 24 h for BMF a, b and HAS2 c and 4 h for SHB d. BMF a, b, HAS2 c, SHB d gene expression was measured by RNA Sequencing and qPCR. The mean of three biological experiments with standard deviation is shown. Statistically significant effects compared to untreated are indicated by *p < 0.05, **p < 0.01 or ***p < 0.001 (one-sample t-test)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us